4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.7% – Time to Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) fell 3.7% on Friday . The company traded as low as $15.48 and last traded at $15.50. Approximately 533,967 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 825,387 shares. The stock had previously closed at $16.10.

Wall Street Analyst Weigh In

Several research analysts have commented on FDMT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.62.

4D Molecular Therapeutics Stock Down 3.9%

The company has a market cap of $854.62 million, a price-to-earnings ratio of -5.88 and a beta of 2.73. The stock’s 50-day moving average is $11.47 and its 200-day moving average is $10.08. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider David Kirn sold 12,415 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the transaction, the insider owned 871,737 shares in the company, valued at $8,760,956.85. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 53.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 200,496 shares of company stock valued at $2,240,244 in the last 90 days. 7.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $76,466,000. RA Capital Management L.P. grew its stake in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares during the period. Janus Henderson Group PLC grew its stake in 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after purchasing an additional 611,276 shares during the period. BlackRock Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $60,463,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 4.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after purchasing an additional 174,489 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.